Editorial: The Art (and Blood Sport) of Psychopharmacology Research: Who Has a Dog in the Fight?
J Clin Psychiatry 2007;68(2):185
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
We wish to highlight 2 Letters to the Editor that appear in this issue. Gharabawi et al. provide commentary on an article published in The Journal of Clinical Psychiatry by Zhong et al. (2006).1 All of the authors of this letter are employed by companies that have a financial interest in the sales of risperidone. The reply is provided by several of the authors of the article published in the Journal, with the particular authors of the response letter (Sweitzer et al.) being employees of another pharmaceutical company, one that sells quetiapine.